The most trusted news from Australia
Provided by AGP
GenEmbryomics Launches XGEN PGT-X™
GenEmbryomics — the first to develop, and global leader in, whole-genome preimplantation genetic testing (PGT) — is taking a clear position: the era of thousands of dollars per embryo-genome tested is over. Clinical-grade comprehensive IVF embryo-genome sequencing is now affordable enough to become routine.
“GenEmbryomics founded the field of IVF genomics by developing the first whole-genome PGT, PGT-WGS. We have spent years solving the next problem: why should the most complete picture of your embryo’s genome cost more than the IVF cycle itself? With XGEN PGT-X™, it no longer does,” said Dr. Nicholas Murphy, CEO at GenEmbryomics.
What This Actually Means
Standard embryo screening (PGT-A) typically checks the embryo chromosome number. XGEN PGT-X™ tells you that and over 3,000 disease-associated genes that chromosomal screening was never designed to find: inherited conditions, de novo mutations, and pathogenic variants that could determine the health trajectory of the child that embryo becomes.
Whole-genome embryo screening has until now been reserved for complex genetic cases and specialist PGT-M cases with appropriate genetic counselling, at prices that put it firmly out of routine reach. XGEN PGT-X™ is something that has never existed before: a complete genomic view of every embryo, for every family, as a routine part of every IVF cycle — without changing a single step of the existing laboratory workflow.
A Truly Personalized IVF Journey
XGEN PGT-X™ is the first time the infrastructure exists to deliver genuinely personalized IVF at scale. Clinics can now offer families real understanding of what each embryo’s genome contains, and what it may reveal about the future health of the child born from that transfer.
XGEN PGT-X™ tells IVF patients more: over 3,000 disease-associated genes — inherited conditions, de novo mutations, and data that could determine the health trajectory of the child that embryo becomes.
XGEN PGT-X™ is available through accredited clinical delivery partners worldwide. Clinics wishing to offer XGEN PGT-X™ may enquire about the XGEN PGT-X™ Early Access Partner Programme at support@genembryomics.com.
Early Access Partner Programme
XGEN PGT-X™ is launching through a structured Early Access Partner Programme. Participating IVF laboratories complete bridging validation and onboarding with GenEmbryomics before clinical offering, in line with their accreditation framework. Programme participation is by application; availability and reporting protocols vary by jurisdiction.
About GenEmbryomics Limited
GenEmbryomics created the world’s first embryo-genome sequencing pipeline for clinical IVF use and coined the term PGT-WGS. Based in Australia and advised by Silverbear Capital LLC, GenEmbryomics develops and licenses XGEN PGT-X™ through qualified IVF genetics laboratory partners worldwide.
Visit www.genembryomics.com for inquiries.
Media Contact
Email: support@genembryomics.com
Web: www.genembryomics.com
Nick Murphy
GenEmbryomics
email us here
Visit us on social media:
LinkedIn
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
